

2025 RELEASE UNDER E.O. 14176

- a2
7. (Amended) The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment of any state with increased endogenous level of CRF or in which the HPA is disregulated, or of a disease induced or facilitated by CRF.
 8. (Amended) The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of any state with increased endogenous level of CRF or in which the HPA is disregulated, or of a disease induced or facilitated by CRF.
 9. (Amended) A method for the treatment of any state with increased endogenous level of CRF or which the HPA is disregulated, or of a disease induced or facilitated by CRF in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form.

REMARKS


By the foregoing amendment to the specification, a cross-reference has been inserted beneath the title of page 1.

Claims 4-9 have been amended to eliminate multiple dependencies and correct editorial errors.

Favorable consideration of this application is respectfully requested.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Respectfully submitted,



Joseph J. Borovian
Agent for Applicant
Reg. No. 26,631

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6921

Date: February 15, 2022